Antisense and RNAi Therapeutics Market Size, Share, And Growth Report 2032

Antisense and RNAi Therapeutics Market

Antisense and RNAi Therapeutics Market by Technology (RNAi [miRNA, and siRNA], and Antisense RNA), by Route of Administration (Pulmonary, Intravenous, Intra-Dermal, Intra-Peritoneal, Topical, and Others), by Indication (Oncology, Cardiovascular Diseases, Renal Diseases, Neurodegenerative Diseases, Respiratory Diseases, Genetic Diseases, Infectious Diseases, and Other Disease Indications), By Region - Global And Regional Industry Overview, market Intelligence, Comprehensive Analysis, Historical Data, And Forecasts 2024-2032

Category: Healthcare Report Format : PDF Pages: 110 Report Code: ZMR-4980 Published Date: Aug-2024 Status : Published
Market Size in 2023 Market Forecast in 2032 CAGR (in %) Base Year
USD 4.69 Billion USD 20.00 Billion 17.5% 2023

Table Of Content

  • Chapter 1. Preface
    • 1.1. Report Description and Scope
    • 1.2. Research Scope
    • 1.3. Research Methodology
      • 1.3.1. Market Research Process
      • 1.3.2. Market Research Methodology
  • Chapter 2. Executive Summary
    • 2.1. Antisense and RNAi Therapeutics Market, 2016-2025 (USD Million)
    • 2.2. Antisense and RNAi Therapeutics Market: Snapshot
  • Chapter 3. Antisense and RNAi Therapeutics Market - Industry Analysis
    • 3.1. Antisense and RNAi Therapeutics Market: Market Dynamics
    • 3.2. Market Drivers
      • 3.2.1. Driver 1
      • 3.2.2. Driver 2
    • 3.3. Restraints
      • 3.3.1. Restraint 1
      • 3.3.2. Restraint 2
    • 3.4. Opportunity
      • 3.4.1. Government funding and support
    • 3.5. Porter's Five Forces Analysis
    • 3.6. Market Attractiveness Analysis
      • 3.6.1. Market attractiveness analysis By Technology
      • 3.6.2. Market attractiveness analysis By Route of Administration
      • 3.6.3. Market attractiveness analysis By Indication
      • 3.6.4. Market attractiveness analysis By Region
  • Chapter 4. Antisense and RNAi Therapeutics Market- Competitive Landscape
    • 4.1. Company market share analysis
      • 4.1.1. Global Antisense and RNAi Therapeutics Market: company market share, 2018
    • 4.2. Strategic development
      • 4.2.1. Acquisitions & mergers
      • 4.2.2. New Technology launches
      • 4.2.3. Agreements, partnerships, collaborations and joint ventures
      • 4.2.4. Research and development and Regional expansion
    • 4.3. Price trend analysis
  • Chapter 5. Global Antisense and RNAi Therapeutics Market -Technology Analysis
    • 5.1. Global Antisense and RNAi Therapeutics Market overview: By Technology
      • 5.1.1. Global Antisense and RNAi Therapeutics Market share, By Technology,2018 and 2025
    • 5.2. RNAi
      • 5.2.1. Global Antisense and RNAi Therapeutics Market By RNAi, 2016-2025 (USD Million)
    • 5.3. miRNA
      • 5.3.1. Global Antisense and RNAi Therapeutics Market By miRNA, 2016-2025 (USD Million)
    • 5.4. siRNA
      • 5.4.1. Global Antisense and RNAi Therapeutics Market By siRNA, 2016-2025 (USD Million)
    • 5.5. Antisense RNA
      • 5.5.1. Global Antisense and RNAi Therapeutics Market By Antisense RNA, 2016-2025 (USD Million)
  • Chapter 6. Global Antisense and RNAi Therapeutics Market -Route of Administration Analysis
    • 6.1. Global Antisense and RNAi Therapeutics Market overview: By Route of Administration
      • 6.1.1. Global Antisense and RNAi Therapeutics Market share, By Route of Administration, 2018 and 2025
    • 6.2. Pulmonary
      • 6.2.1. Global Antisense and RNAi Therapeutics Market By Pulmonary, 2016-2025 (USD Million)
    • 6.3. Intravenous
      • 6.3.1. Global Antisense and RNAi Therapeutics Market By Intravenous, 2016-2025 (USD Million)
    • 6.4. Intra-dermal
      • 6.4.1. Global Antisense and RNAi Therapeutics Market By Intra-dermal, 2016-2025 (USD Million)
    • 6.5. Intra-peritoneal
      • 6.5.1. Global Antisense and RNAi Therapeutics Market By Intra-peritoneal, 2016-2025 (USD Million)
    • 6.6. Topical
      • 6.6.1. Global Antisense and RNAi Therapeutics Market By Topical Route of Administrations, 2016-2025 (USD Million)
    • 6.7. Others
      • 6.7.1. Global Antisense and RNAi Therapeutics Market By Other Route of Administrations, 2016-2025 (USD Million)
  • Chapter 7. Global Antisense and RNAi Therapeutics Market -Indication Analysis
    • 7.1. Global Antisense and RNAi Therapeutics Market overview: By Indication
      • 7.1.1. Global Antisense and RNAi Therapeutics Marketshare, By Indication, 2018 and 2025
    • 7.2. Oncology
      • 7.2.1. Global Antisense and RNAi Therapeutics Market By Oncology, 2016-2025 (USD Million)
    • 7.3. Cardiovascular Diseases
      • 7.3.1. Global Antisense and RNAi Therapeutics Market By Cardiovascular Diseases, 2016-2025 (USD Million)
    • 7.4. Renal Diseases
      • 7.4.1. Global Antisense and RNAi Therapeutics Market By Renal Diseases, 2016-2025 (USD Million)
    • 7.5. Neurodegenerative Diseases
      • 7.5.1. Global Antisense and RNAi Therapeutics MarketBy others4, 2016-2025 (USD Million)
    • 7.6. Respiratory Diseases
      • 7.6.1. Global Antisense and RNAi Therapeutics Market By Respiratory Diseases, 2016-2025 (USD Million)
    • 7.7. Genetic Diseases
      • 7.7.1. Global Antisense and RNAi Therapeutics Market By Genetic Diseases, 2016-2025 (USD Million)
    • 7.8. Infectious Diseases
      • 7.8.1. Global Antisense and RNAi Therapeutics Market By Infectious Diseases, 2016-2025 (USD Million)
    • 7.9. Other Disease Indications
      • 7.9.1. Global Antisense and RNAi Therapeutics Market By Other Disease Indications, 2016-2025 (USD Million)
  • Chapter 8. Global Antisense and RNAi Therapeutics Market - Regional Analysis
    • 8.1. Global Antisense and RNAi Therapeutics Market overview: By Region
      • 8.1.1. Global Antisense and RNAi Therapeutics Marketshare, By Region, 2018 and 2025
    • 8.2. North America
      • 8.2.1. North America Antisense and RNAi Therapeutics Market, 2016-2025 (USD Million)
      • 8.2.2. North America Antisense and RNAi Therapeutics Market revenue, By Technology,2016-2025 (USD Million)
      • 8.2.3. North America Antisense and RNAi Therapeutics Marketrevenue, By Route of Administration, 2016-2025 (USD Million)
      • 8.2.4. North America Antisense and RNAi Therapeutics Market revenue, By Indication, 2016-2025 (USD Million)
      • 8.2.5. The U.S.
        • 8.2.5.1. The U.S.Antisense and RNAi Therapeutics Market revenue, By Technology,2016-2025 (USD Million)
        • 8.2.5.2. The U.S.Antisense and RNAi Therapeutics Market revenue, By Route of Administration, 2016-2025 (USD Million)
        • 8.2.5.3. The U.S.Antisense and RNAi Therapeutics Market revenue, By Indication, 2016-2025 (USD Million)
      • 8.2.6. Rest of North America
        • 8.2.6.1. Rest of North America Antisense and RNAi Therapeutics Market revenue, By Technology,2016-2025 (USD Million)
        • 8.2.6.2. Rest of North America Antisense and RNAi Therapeutics Market revenue, By Route of Administration, 2016-2025 (USD Million)
        • 8.2.6.3. Rest of North America Antisense and RNAi Therapeutics Market revenue, By Indication, 2016-2025 (USD Million)
    • 8.3. Europe
      • 8.3.1. EuropeAntisense and RNAi Therapeutics Market2016-2025 (USD Million)
      • 8.3.2. Europe Antisense and RNAi Therapeutics Market revenue, By Technology,2016-2025 (USD Million)
      • 8.3.3. Europe Antisense and RNAi Therapeutics Market revenue, By Route of Administration, 2016-2025 (USD Million)
      • 8.3.4. Europe Antisense and RNAi Therapeutics Marketrevenue, By Indication, 2016-2025 (USD Million)
      • 8.3.5. UK
        • 8.3.5.1. U.K.Antisense and RNAi Therapeutics Market revenue, By Technology,2016-2025 (USD Million)
        • 8.3.5.2. U.K.Antisense and RNAi Therapeutics Market revenue, By Route of Administration, 2016-2025 (USD Million)
        • 8.3.5.3. U.K. Antisense and RNAi Therapeutics Marketrevenue, By Indication, 2016-2025 (USD Million)
      • 8.3.6. France
        • 8.3.6.1. France Antisense and RNAi Therapeutics Market revenue, By Technology,2016-2025 (USD Million)
        • 8.3.6.2. France Antisense and RNAi Therapeutics Market revenue, By Route of Administration, 2016-2025 (USD Million)
        • 8.3.6.3. France Antisense and RNAi Therapeutics Market revenue, By Indication, 2016-2025 (USD Million)
      • 8.3.7. Germany
        • 8.3.7.1. Germany Antisense and RNAi Therapeutics Market revenue, By Technology,2016-2025 (USD Million)
        • 8.3.7.2. Germany Antisense and RNAi Therapeutics Marketrevenue, By Route of Administration, 2016-2025 (USD Million)
        • 8.3.7.3. Germany Antisense and RNAi Therapeutics Market revenue, By Indication, 2016-2025 (USD Million)
      • 8.3.8. Rest of Europe
        • 8.3.8.1. Rest of EuropeAntisense and RNAi Therapeutics Market revenue, By Technology,2016-2025 (USD Million)
        • 8.3.8.2. Rest of EuropeAntisense and RNAi Therapeutics Marketrevenue, By Route of Administration, 2016-2025 (USD Million)
        • 8.3.8.3. Rest of Europe Antisense and RNAi Therapeutics Market revenue, By Indication, 2016-2025 (USD Million)
    • 8.4. Asia Pacific
      • 8.4.1. Asia Pacific Antisense and RNAi Therapeutics Market, 2016-2025 (USD Million)
      • 8.4.2. Asia Pacific Antisense and RNAi Therapeutics Marketrevenue, By Technology,2016-2025 (USD Million)
      • 8.4.3. Asia Pacific Antisense and RNAi Therapeutics Market revenue, By Route of Administration, 2016-2025 (USD Million)
      • 8.4.4. Asia Pacific Antisense and RNAi Therapeutics Marketrevenue, By Indication, 2016-2025 (USD Million)
      • 8.4.5. China
        • 8.4.5.1. China Antisense and RNAi Therapeutics Market revenue, By Technology,2016-2025 (USD Million)
        • 8.4.5.2. China Antisense and RNAi Therapeutics Market revenue, By Route of Administration, 2016-2025 (USD Million)
        • 8.4.5.3. China Antisense and RNAi Therapeutics Marketrevenue, By Indication, 2016-2025 (USD Million)
      • 8.4.6. Japan
        • 8.4.6.1. Japan Antisense and RNAi Therapeutics Market revenue, By Technology,2016-2025 (USD Million)
        • 8.4.6.2. Japan Antisense and RNAi Therapeutics Marketrevenue, By Route of Administration, 2016-2025 (USD Million)
        • 8.4.6.3. Japan Antisense and RNAi Therapeutics Market revenue, By Indication, 2016-2025 (USD Million)
      • 8.4.7. India
        • 8.4.7.1. India Antisense and RNAi Therapeutics Market revenue, By Technology,2016-2025 (USD Million)
        • 8.4.7.2. India Antisense and RNAi Therapeutics Marketrevenue, By Route of Administration, 2016-2025 (USD Million)
        • 8.4.7.3. India Antisense and RNAi Therapeutics Market revenue, By Indication, 2016-2025 (USD Million)
      • 8.4.8. Rest of Asia Pacific
        • 8.4.8.1. Rest of Asia Pacific Antisense and RNAi Therapeutics Marketrevenue, By Technology,2016-2025 (USD Million)
        • 8.4.8.2. Rest of Asia Pacific Antisense and RNAi Therapeutics Market revenue, By Route of Administration, 2016-2025 (USD Million)
        • 8.4.8.3. Rest of Asia Pacific Antisense and RNAi Therapeutics Market revenue, By Indication, 2016-2025 (USD Million)
    • 8.5. Latin America
      • 8.5.1. Latin America Antisense and RNAi Therapeutics Market, 2016-2025 (USD Million)
      • 8.5.2. Latin America Antisense and RNAi Therapeutics Market revenue, By Technology,2016-2025 (USD Million)
      • 8.5.3. Latin America Antisense and RNAi Therapeutics Market revenue, By Route of Administration, 2016-2025 (USD Million)
      • 8.5.4. Latin America Antisense and RNAi Therapeutics Market revenue, By Indication, 2016-2025 (USD Million)
      • 8.5.5. Brazil
        • 8.5.5.1. Brazil Antisense and RNAi Therapeutics Marketrevenue, By Technology,2016-2025 (USD Million)
        • 8.5.5.2. Brazil Antisense and RNAi Therapeutics Market revenue, By Route of Administration, 2016-2025 (USD Million)
        • 8.5.5.3. Brazil Antisense and RNAi Therapeutics Market revenue, By Indication, 2016-2025 (USD Million)
      • 8.5.6. Rest of LatinAmerica
        • 8.5.6.1. Rest of LatinAmerica Antisense and RNAi Therapeutics Market revenue, By Technology,2016-2025 (USD Million)
        • 8.5.6.2. Rest of LatinAmerica Antisense and RNAi Therapeutics Market revenue, By Route of Administration, 2016-2025 (USD Million)
        • 8.5.6.3. Rest of Latin America Antisense and RNAi Therapeutics Marketrevenue, By Indication, 2016-2025 (USD Million)
    • 8.6. The Middle East and Africa
      • 8.6.1. The Middle East and Africa Antisense and RNAi Therapeutics Market, 2016-2025 (USD Million)
      • 8.6.2. The Middle East and Africa Antisense and RNAi Therapeutics Marketrevenue, By Technology,2016-2025 (USD Million)
      • 8.6.3. The Middle East and Africa Antisense and RNAi Therapeutics Market revenue, By Route of Administration, 2016-2025 (USD Million)
      • 8.6.4. The Middle East and Africa Antisense and RNAi Therapeutics Marketrevenue, By Indication, 2016-2025 (USD Million)
  • Chapter 9. Company Profiles
    • 9.1. Alnylam Pharmaceuticals
      • 9.1.1. Overview
      • 9.1.2. Financials
      • 9.1.3. Technology Portfolio
      • 9.1.4. Business Strategy
      • 9.1.5. Recent Developments
    • 9.2. Isis Pharmaceuticals
      • 9.2.1. Overview
      • 9.2.2. Financials
      • 9.2.3. Technology Portfolio
      • 9.2.4. Business Strategy
      • 9.2.5. Recent Developments
    • 9.3. Silence Therapeutics
      • 9.3.1. Overview
      • 9.3.2. Financials
      • 9.3.3. Technology Portfolio
      • 9.3.4. Business Strategy
      • 9.3.5. Recent Developments
    • 9.4. Santaris
      • 9.4.1. Overview
      • 9.4.2. Financials
      • 9.4.3. Technology Portfolio
      • 9.4.4. Business Strategy
      • 9.4.5. Recent Developments
    • 9.5. Antisense Therapeutics
      • 9.5.1. Overview
      • 9.5.2. Financials
      • 9.5.3. Technology Portfolio
      • 9.5.4. Business Strategy
      • 9.5.5. Recent Development
    • 9.6. miRagen Therapeutics.
      • 9.6.1. Overview
      • 9.6.2. Financials
      • 9.6.3. Technology Portfolio
      • 9.6.4. Business Strategy
      • 9.6.5. Recent Development

Methodology

FrequentlyAsked Questions

Antisense and RNA interference (RNAi) therapeutics are advanced molecular approaches used to target and modify gene expression for therapeutic purposes.

According to study, the Antisense and RNAi Therapeutics Market size was worth around USD 4.69 billion in 2023 and is predicted to grow to around USD 20.00 billion by 2032.

The CAGR value of Antisense and RNAi Therapeutics Market is expected to be around 17.5% during 2024-2032.

North America has been leading the Antisense and RNAi Therapeutics Market and is anticipated to continue on the dominant position in the years to come.

The Antisense and RNAi Therapeutics Market is led by players like Alnylam Pharmaceuticals, Isis Pharmaceuticals, Silence Therapeutics, Santaris, Antisense Therapeutics, and miRagen Therapeutics.

  • zion payment modes

List of Contents

Market SizeOverviewSegmentationReport ScopeRegional AnalysisThis report segments the global antisense and RNAi therapeutics market as follows:RNAi

HappyClients